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FISH analysis of PTEN in endometrial carcinoma. Comparison with SNP arrays and MLP
Aims: To check the usefulness of a standardized pro-
tocol of PTEN FISH in 31 endometrial carcinomas
(ECs) in comparison with SNP array (SNPA), multi-
plex ligation-dependent probe amplification (MLPA),
and immunohistochemistry.
Methods and results: Fluorescence in-situ hybridiza-
tion analysis showed two PTEN copies in 17 cases,
three copies in nine cases, hemizygous deletion in
two cases, and diverse cell populations with different
PTEN copy number in three cases. A good correlation
was seen between FISH and SNPA, particularly in
cases with three copies. FISH identified two cases
with entire deletion of chromosome 10, but did not
identify a focal deletion of PTEN. Five cases with
PTEN deletion and duplication of the second allele by
SNPA were interpreted as normal by FISH. Concor-
dance between FISH and MLPA was seen in 15 cases
with two copies, and in two cases with PTEN dele-
tion. Six cases were interpreted as amplified by
MLPA, but showed polyploidy by FISH. FISH was
superior to SNPA and MLPA in assessing the
tumours with diverse cell populations with different
PTEN copies.
Conclusions: The results show good concordance
between FISH, SNPA and MLPA. SNPA was superior
in tumours with deletion of one copy and duplication
of the second allele. FISH was superior in assessing
tumour heterogeneity.
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Introduction
PTEN (phosphatase and tensin homologue deleted on
chromosome 10) has been identified as a tumour
suppressor gene,1 and is mutated in a large number
of cancers.2–10 It is rather than cancers, it is located
at 10q23.31. PTEN is a phosphatidylinositol-3,4,5-
trisphosphate 3-phosphatase containing a tensin-like
domain as well as a catalytic domain similar to that
of the dual-specificity protein tyrosine phosphatases.11
Unlike most of the protein tyrosine phosphatases, this
protein preferentially dephosphorylates phosphoinosi-
tide substrates.12 It negatively regulates the PI3K–
Akt signalling pathway.13
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Somatic alterations of PTEN, including point muta-
tions, insertions, and deletions, occur throughout the
whole gene in a significant proportion of sporadic
cancers. In some cases, PTEN deletion occurs in the
setting of large chromosomal losses involving the
whole of chromosome 10.14 In other instances, dele-
tions are restricted to the entire PTEN gene, or to a
few exons.15 Loss of heterozygosity (LOH) at 10q23
occurs in 40% of endometrial carcinomas (ECs).16
Deletions may be hemizygous or homozygous. PTEN
being a tumour suppressor gene, two hits are com-
mon for PTEN loss of function, and deletion of PTEN
is commonly the second hit. However, more recently,
it has become clear that one alteration may be suffi-
cient for PTEN inactivation.17,18 Interestingly, when
a tumour has chromosomal instability, three copies of
PTEN can be seen, as a result of polysomy of chromo-
some 10.19 The biological significance of chromosome
10 polysomy, and the consequences for PTEN levels,
have not been fully elucidated.
In some types of cancer, PTEN alteration is an early
event, being involved in the initial steps of the process
of neoplastic development.20 In these cases, alterations
of PTEN are seen to be homogeneously distributed in
the tumours. However, in other cases, PTEN abnormal-
ities occur in the process of tumour progression,8,21
and PTEN alterations can be detected in specific
regions of the tumour. The heterogeneous involvement
of PTEN in a tumour may be demonstrated by immu-
nohistochemistry.22 However, decreased PTEN expres-
sion does not necessarily reflect the presence of LOH at
10q23, as it may result from PTEN point mutations,
and also from promoter hypermethylation, transcrip-
tional repression, microRNA regulation, disruption of
competitive endogenous RNA networks, or post-trans-
lational modification.19,23
Fluorescence in-situ hybridization (FISH) may be
used to detect cytogenetic aberrations,24 such as dele-
tions,25 duplications,26 amplifications27 and structural
abnormalities of specific genes, loci, or chromosomal
sequences.28 The regions assessed with FISH are typi-
cally larger than those studied with polymerase chain
reaction (PCR), but smaller than those visualized micro-
scopically with standard cytogenetics. Studies have
demonstrated that FISH analysis of PTEN can identify
groups of tumours with different prognoses among
prostatic carcinomas28 and rectal carcinomas.29
In the present study, we developed a standardized
protocol for PTEN FISH to detect PTEN copy number
alterations (see Supporting Information) in a series of
ECs in comparison with results obtained by single
nucleotide polymorphism array (SNPA) and multiplex
ligation-dependent probe amplification (MLPA). We
used the fast IQ hybridization buffer technology (IQ-
FISH; Dako, Glostrup, Denmark).30 We assessed the
role of FISH in evaluating the heterogeneous presence
of PTEN copy number alterations in the tumours.
Finally, we compared the molecular results with the
levels of PTEN protein determined by immunohisto-
chemistry, in an attempt to correlate PTEN copy
number alterations with PTEN loss.
Materials and methods
C A S E S E L E C T I O N
A series of 31 ECs were studied. Formalin-fixed paraf-
fin-embedded (FFPE) blocks were available for FISH
and immunohistochemistry. Matched frozen tissue
samples were selected for SNPA and MLPA. Haemat-
oxylin and eosin (H&E) sections were obtained to con-
firm that frozen samples corresponded to the same
areas as the FFPE material. The tumours were
obtained from the files of Hospital Universitari Arnau
de Vilanova, Lleida, Spain (HUAV). The local Ethics
Committee approved the study. Informed consent was
obtained from each patient. Pathological features of
the tumours (histological type, grade, and stage) are
summarized in Table 1.
For evaluation of preanalytical variables, two
additional surgical specimens were used, obtained
from the surgical pathology files of HUAV. They
corresponded to ECs removed by hysterectomy and
bilateral salpingoophorectomy. Surgical specimens
were obtained from the operating room, immediately
after resection. Cases were recruited because the size
of the tumours allowed the selection of different
small fragments to test the high number of vari-
ables. Tissue subjected to preanalytical factor evalu-
ation of PTEN FISH was obtained from the excess
material after selection of tissue samples for appro-
priate diagnosis.
F L U O R E S C E N C E I N - S I T U H Y B R I D I Z A T I O N
Formalin-fixed paraffin-embedded blocks were sec-
tioned at a thickness of 3 lm, dried for 1 h at 65°C,
deparaffinized, and rehydrated. A pretreatment was
performed in a microwave oven with a sensing capa-
bility for 10 min at 95°C, and the sections were then
left for 15 min at room temperature (20–25°C). Pep-
sin digestion was performed using pepsin RTU (ready
to use) at 37°C. The PTEN IQFISH probe used for
hybridization was made as a mixture of a DNA-based
Texas Red (TxR) probe specific for PTEN and a PNA-
based, fluorescein isothiocyanate (FITC)-labelled refer-
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Table 1. Summary of pathological features of the tumours and analysis by FISH
No PTEN/CEN10 ratio % FISH result Histological type Grade Stage
1 0.97 72 Polysomy (three copies) SC III IA
2 1.02 76 Normal (two copies) EEC II IB
3 1.13 81 Normal (two copies) EEC II IB
4 0.84 77 Normal (two copies) EEC I IA
5 1.1 86 Normal (two copies) EEC I IA
6 1.13 73 Polysomy (three copies) EEC II IB
7 1.05 79 Normal (two copies) EEC II IA
8 0.96 71 Polysomy (three copies) SC III IB
9 0.91 83 Normal (two copies) EEC III IB





(C1, polysomy; C2, normal)
SC III IA
11 0.93 74 Normal (two copies) EEC II IB
12 1.02 85 Polysomy (three copies) EEC II IB
13 1.05 76 Normal (two copies) EEC II IA
14 0.98 78 Normal (two copies) EEC II IA





(C1, hemizygous deletion; C2, normal)
EEC I IA
16 1.1 74 Polysomy (three copies) EEC II IA
17 1.12 79 Normal (two copies) EEC III IB
18 0.95 71 Normal (two copies) EEC III IB
19 0.63 81 Hemizygous deletion (one copy) EEC III IA
20 1.08 73 Polysomy (three copies) EEC II IB
21 0.95 77 Normal (two copies) EEC III IB





(C1, polysomy; C2, normal)
EEC II IA
23 0.94 83 Normal (two copies) SC III IB
24 0.98 81 Normal (two copies) EEC I IA
25 1.12 74 Polysomy (three copies) EEC II IB
26 0.56 77 Hemizygous deletion (one copy) EEC III II
27 1.04 78 Normal (two copies) EEC III II
28 0.92 75 Normal (two copies) EEC II IA
29 1.13 72 Polysomy (three copies) EEC III IB
30 1.1 74 Normal (two copies) EEC III IB
31 0.97 82 Polysomy (three copies) EEC I IB
EEC, Endometrioid carcinoma; SC, serous carcinoma.
© 2014 John Wiley & Sons Ltd, Histopathology, 65, 371–388.
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ence probe specific for the centromeric region of chro-
mosome 10 (CEN10); the probe was a gift from Dako.
We used the fast IQ hybridization buffer technology
(IQFISH), which utilizes ethylene carbonate rather
than formamide as the DNA-destabilizing component.
Consequently, the IQFISH buffer is non-toxic, and
also reduces the time needed for hybridization to
genomic targets. The total turn-around time for FISH
staining with an IQFISH-based probe is therefore
<4 h. The IQFISH probe was incubated in Dako
Hybridizer in two steps: denaturation at 66°C for
10 min, and hybridization at 45°C for a maximum of
2 h. After hybridization, a stringent wash was per-
formed for 10 min at 63°C with a stringent wash
buffer. Finally, samples were dehydrated, and nuclei
were stained with DAPI. All reagents (wash buffer,
pretreatment buffer, stringent buffer, and pepsin RTU)
were obtained from the Histology FISH Accessory Kit
(K5799; Dako). Signals were counted under a micro-
scope equipped with a 9100 objective, with a tetram-
ethylrhodamine isothiocyanate (TRITC) philtre, an
FITC philtre, and a TxR/FITC double philtre.
P T E N F I S H S C O R I N G
For evaluation of the results of FISH, several factors
were taken into account to select the optimal tumour
sections for PTEN FISH scoring, as rigorous quality
criteria for suitability for FISH analysis. They
included: preservation of tissue architecture, fixation
artefacts, tumour cellularity within the section, and
the absence of truncated nuclei and irregular glandu-
lar distortions. Areas selected for FISH evaluation
were marked on an H&E-stained section that was
directly adjacent to the section being used for FISH.
Tissue areas were considered to be appropriate for
FISH analysis after meeting rigorous criteria: (i) at
least 85% of all nuclei in the target area were easily
enumerable; (ii) the FISH signal was consistently
greater than background intensity; (iii) areas where
the borders of individual nuclei were not clearly iden-
tifiable were avoided; (iv) areas with excessive
nuclear overlap were disregarded; (v) similar signal
staining in the nuclei; and (vi) uniform DAPI stain-
ing. Staining of adjacent normal tissue was checked
as reference. We required ~100 tumour cell nuclei to
be analysed for each sample, depending upon the
density of cancer cells. In complex tissue where there
was more than one type of aberration, each of them
was scored individually (scoring 100 cells for each).
We established five different statuses for PTEN
FISH. First, normal PTEN copy number was charac-
terized by the presence of two green (CEN10) and
two red (PTEN) signals in a minimum of 70% of
nuclei, and a PTEN/CEN10 ratio (number of PTEN
signals/number of CEN10 signals) between 0.8 and
1.2. Second, PTEN hemizygous deletion was charac-
terized by the presence of two green (CEN10) signals
and one red (PTEN) signal in a minimum of 70% of
nuclei, and a PTEN/CEN10 ratio of <0.8. Third, PTEN
gene homozygous deletion was characterized by the
presence of two green (CEN10) signals and no red
(PTEN) signal in a minimum of 70% of nuclei, and a
PTEN/CEN10 ratio between 0 and 0.2. Fourth, whole
chromosome 10 deletion was characterized by the
presence of one green (CEN10) and one red (PTEN)
signal in a minimum of 70% of nuclei, and a PTEN/
CEN10 ratio between 0.8 and 1.2. Fifth, increased
PTEN copy number (polysomy) was characterized by
the presence of three green (CEN10) and red (PTEN)
signals in a minimum of 70% of nuclei, and a PTEN/
CEN10 ratio between 0.8 and 1.2.31 The criteria for
scoring PTEN by FISH were obtained after taking into
account the previous experience of the research team
and data from the literature.32 The scoring system
was validated with 25 cases of normal endometrial
tissue. In all cases, the PTEN score fitted within the
ranges of normal PTEN copy number.
S N P A R R A Y
The Human CytoSNP array (Illumina; San Diego, CA,
USA) was used to detect 240 000 SNPs evenly dis-
tributed across the genome, according to the manu-
facturer’s protocol. ASCAT (allele-specific copy
number analysis of tumours) was used to dissect the
allele-specific copy numbers of solid tumours. On the
basis of the observed B-allele frequency and logR ratio
of each SNP, chromosomal amplifications, deletions
and copy-neutral loss of heterozygosity were detected
at the genome-wide level.
M U L T I P L E X L I G A T I O N - D E P E N D E N T P R O B E
A M P L I F I C A T I O N
We used SALSA MLPA probe-mix P225-C1 PTEN
(MRC-Holland; Amsterdam, The Netherlands). This
probe-mix contains at least two probes for each of the
nine exons; the total number of PTEN probes included
is 20. It also contains: 13 probes located elsewhere on
chromosome 10 that can help to distinguish focal
PTEN deletions in tumour-derived DNA samples from
loss of the complete 10q arm or a chromosome 10
aneuploidy; two probes for copy number detection of
the pseudogene PTENP1 (at 9p13.3); and 15 reference
probes. A DNA extraction was used (DNeasy Blood and
© 2014 John Wiley & Sons Ltd, Histopathology, 65, 371–388.
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Tissue Kit; Qiagen, Hilden, Germany). The MLPA assay
was performed according to the manufacturer’s proto-
col (MLPA DNA protocol version MDP-v002). After
fragment separation by capillary electrophoresis
(Applied Biosystems; Foster City, CA, USA), an evalua-
tion of the raw data was performed using GeneMapper.
The results were always normalized and compared
with strict external controls such as blood samples and
non-tumour samples.
I M M U N O H I S T O C H E M I S T R Y
Formalin-fixed paraffin-embedded sections were evalu-
ated by applying our optimized PTEN staining immuno-
histochemistry assay.33 Sections were obtained at a
thickness of 3 lm, dried for 1 h at 65°C, deparaffinized,
rehydrated, and subjected to target retrieval in the pre-
treatment module PT Link (Dako) at 95°C for 20 min
in Target Retrieval Solution (pH 9) (Dako). Endogenous
peroxidase was blocked using peroxidase-blocking
reagent (Dako), and this was followed by incubation
with primary PTEN antibody (clone 6H2.1; Dako). The
incubation time for the primary antibody was 40 min.
EnVision FLEX+/HRP (Dako) (20 + 15 min) was used
to amplify signal, and detection was done using 3,30-di-
aminobenzidine tetrahydrochloride (DAB) as chromo-
gen (Dako). Slides were counterstained with
haematoxylin, dehydrated, and mounted. PTEN expres-
sion was nuclear and cytoplasmic. Appropriate nega-
tive controls were also tested: these involved omission
of the primary antibody, and the inclusion of tissue
samples known to show PTEN silencing. We used a his-
tological staining score (Hscore) that takes into consid-
eration the intensity of the staining, and the percentage
of positive cells, by applying the formula:
Hscore = (1 9 % light staining) + (2 9 % moderate
staining) + (3 9 % strong staining). This gives a score
ranging from 0 (no immune reaction) to 300 (maximal
immunoreactivity).
S T A T I S T I C A L A N A L Y S I S
Fisher’s exact test was used to correlate PTEN expres-
sion as detected by immunohistochemistry with PTEN
copies as detected by SNPA, MLPA, and FISH.
Results
F I S H S C O R I N G
Results from the analysis of the 31 ECs are shown in
Table 1. Seventeen cases showed a normal PTEN
copy number, nine showed three copies (polysomy 3),
and two cases had hemizygous deletion of PTEN (one
copy). The presence of more than one tumour cell
population with differences regarding PTEN copy
number was seen in three cases. In one case (case
10), 44% of tumour cells showed three copies of
PTEN (polysomy), and 56% showed a normal copy
number. In the second case (case 15), 42% of tumour
cells showed hemizygous deletion of PTEN, and 58%
showed a normal copy number. In the third case
(case 22), 40% of tumour cells showed three copies
of PTEN (polysomy), and 60% showed a normal copy
number. Representative pictures are shown in Fig-
ures 1–7.
S N P A R R A Y
Table 2 shows the correlation between FISH and
SNPA after exclusion of the three cases that showed
heterogeneous populations by FISH, which will be
presented separately. A normal PTEN copy number
was seen in 11 of 31 cases. Three copies of PTEN
were identified in nine cases. An absolute correlation
between FISH and SNPA was achieved in cases
showing three copies of PTEN. Hemizygous deletion
of the whole of chromosome 10 (one copy of chro-
mosome 10) was seen in two cases. A hemizygous
deletion restricted to PTEN was seen in one case. In
five cases, SNP analysis showed hemizygous deletion
of one PTEN allele with duplication of the second
allele. Overall, deletion of PTEN was seen in eight of
31 cases (26%), although, in five of them, there was
also duplication of the second allele. Fluorescence in-
situ hybridization identified the two cases with dele-
tion of the whole of chromosome 10. However, FISH
did not identify the only case with focal deletion of
PTEN. The five cases of PTEN deletion and duplica-
tion of the second allele were interpreted as normal
by FISH.
M U L T I P L E X L I G A T I O N - D E P E N D E N T P R O B E
A M P L I F I C A T I O N
Table 3 shows the correlation between MLPA results
and those obtained by FISH; and Table 4 the corre-
lation between MLPA results and those obtained by
SNPA. In both Tables the three cases that showed
heterogeneous populations by FISH have been
excluded. A normal PTEN copy number was seen in
17 cases, four cases showed one copy of PTEN, six
cases showed PTEN amplification, and one case
showed a complex PTEN status (amplification and
deletion). Fifteen cases had a concordant normal
diploid pattern by FISH and MLPA, and two had
© 2014 John Wiley & Sons Ltd, Histopathology, 65, 371–388.
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two copies by MLPA and three copies by FISH. Two
cases had a concordant pattern of PTEN deletion by
FISH and MLPA, whereas results were discordant in
two additional cases. Six cases were interpreted as
amplified by MLPA, but showed polyploidy by FISH.
One case with a complex MLPA pattern (amplifica-





























Figure 1. An endometrial carcinoma with normal PTEN status (case 17). A, SNPA image showing normal PTEN. B, MLPA with normal
PTEN in tumour tissue (T) as compared with normal tissue control (N). C, FISH image showing cells with two copies of PTEN. D, Positive
immunostaining for PTEN.
© 2014 John Wiley & Sons Ltd, Histopathology, 65, 371–388.
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A concordant normal pattern (two copies) was seen in
11 cases with SNPA and MLPA. Six cases showed ampli-
fication by MLPA and polysomy by SNPA, but discordant
results were obtained in three additional cases, which
were interpreted as polyploid by SNPA. Five cases showed
deletion and duplication of the second allele by SNPA,
and four of them were interpreted as normal by MLPA



























Figure 2. An endometrial carcinoma with a PTEN deletion (case 26). A, SNPA image showing deletion of chromosome 10. B, MLPA with
deleted PTEN; arrows indicate deleted areas in tumour tissue (T) as compared with normal tissue control (N). C, FISH image showing one
copy of chromosome 10. D, Negative immunostaining for PTEN.
© 2014 John Wiley & Sons Ltd, Histopathology, 65, 371–388.




























Figure 3. An endometrial carcinoma with polysomy of chromosome 10 (case 1). A, SNPA image showing three copies of PTEN. B, MLPA
with amplification of exons 1 and 9 in tumour tissue (T) as compared with normal tissue control (N). C, FISH image showing cells with
three copies of chromosome 10. D, Positive immunostaining for PTEN.
© 2014 John Wiley & Sons Ltd, Histopathology, 65, 371–388.




























Figure 4. An endometrial carcinoma with deletion of PTEN and duplication of the second allele (case 14). A, SNPA image showing one
PTEN allele deleted and the second allele duplicated. B, MLPA with normal PTEN status in tumour tissue (T) as compared with normal tis-
sue control (N). C, FISH image showing cells with two copies of PTEN. D, Negative immunostaining for PTEN.
© 2014 John Wiley & Sons Ltd, Histopathology, 65, 371–388.



























Figure 5. An example of an endometrial carcinoma with heterogeneous distribution of PTEN copy number (case 10). A, SNPA showing
three copies of PTEN. B, MLPA with normal PTEN in both tumour tissue (T) and normal tissue control (N). C, D, FISH image showing a
group of cells with two copies of PTEN (C) and a group of cells with three copies of PTEN (D). E, F, Immunohistochemistry shows negative
staining for PTEN in some areas (E), and positive immunostaining in others (F).
© 2014 John Wiley & Sons Ltd, Histopathology, 65, 371–388.



























Figure 6. An example of an endometrial carcinoma with heterogeneous distribution of PTEN copy number (case 15). A, SNPA showing one
allele of PTEN deleted and the second allele duplicated. B, MLPA with normal PTEN in both tumour tissue (T) and normal tissue control
(N). C, D, FISH image showing a group of cells with two copies of PTEN (C) and a group of cells with complete deletion of chromosome 10
(D). E, F, Negative PTEN immunostaining in the two areas.
© 2014 John Wiley & Sons Ltd, Histopathology, 65, 371–388.



























Figure 7. An example of an endometrial carcinoma with heterogeneous distribution of PTEN copy number (case 22). A, SNPA showing one
allele of PTEN deleted and the second duplicated. B, MLPA with normal PTEN in both tumour tissue (T) and normal tissue control (N). C, D,
FISH image showing a group of cells with two copies of PTEN (C) and a group of cells with three copies of PTEN (D). E, F, Immunohisto-
chemistry shows cells with negative staining (E) and positive staining (F) for PTEN.
© 2014 John Wiley & Sons Ltd, Histopathology, 65, 371–388.
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I M M U N O H I S T O C H E M I S T R Y
Tables 5, 6 and S1 show the results of analysis of the
relationship between immunohistochemistry and the
results obtained with the three molecular techniques
(FISH, SNPA, and MLPA), after exclusion of the three
cases that showed heterogeneous populations by
FISH. Interestingly, tumours showing polysomy by
FISH and SNPA (interpreted as amplified by MLPA)
showed similar PTEN expression as tumours with a
normal PTEN copy number (P = 0.68 and P = 1,
respectively). In contrast, cases showing deletion of
PTEN by FISH, SNPA or MLPA showed decreased
expression of PTEN, even in the presence of duplica-
tion of the second allele, although statistical signifi-
cance was not reached.
T U M O U R S W I T H H E T E R O G E N E O U S P T E N
A L T E R A T I O N S
The three cases that showed a heterogeneous distri-
bution of PTEN by FISH were interpreted separately
(Table 7; Figures 5–7). The first case (case 10) con-
tained one cell population with three copies of chro-
mosome 10 (44%) and a second population with a
normal copy number (two copies) (56%). The case
was interpreted as containing three copies by SNPA
and containing two copies by MLPA. Interestingly,
immunohistochemical expression of PTEN was heter-
ogeneous in the tumour. Although there was not an
absolute correlation, the areas with polysomy showed
increased PTEN immunostaining in comparison with
tumour areas with a normal PTEN copy number. The
second case (case 15) contained a tumour cell popu-
lation with a PTEN deletion (42%), and a population
with a normal copy number (58%). The tumour was
interpreted as having one allele deleted and duplica-
tion of a second allele by SNPA, and as having a
Table 2. Correlation between FISH and SNP array in 28





















Table 3. Correlation between multiplex ligation-dependent
probe amplification (MLPA) and FISH in 28 cases; three

















Table 4. Correlation between SNP array and multiplex ligation-dependent probe amplification (MLPA) in 28 cases; three
cases with heterogeneous alteration of PTEN by FISH are excluded
SNP array
MLPA
Normal Deletion Amplification Amplification plus deletion
Two copies 11
Three copies 2 1 6
One copy 2
Focal deletion 1
Deletion plus duplication of the second allele 4 1
© 2014 John Wiley & Sons Ltd, Histopathology, 65, 371–388.
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normal copy number by MLPA. Immunohistochemical
expression of PTEN was also homogeneously negative
in the two components. The third case (case 22) con-
tained one cell population with three copies of chro-
mosome 10 (40%) and a second population with a
normal copy number (two copies) (60%). The tumour
was interpreted as having one allele deleted and
duplication of a second allele by SNPA, and as having
a normal copy number by MLPA. Immunohistochem-
ical expression of PTEN was also heterogeneous.
Discussion
Tumour suppressor genes (TSGs) such as PTEN are
important in tumorigenesis. Although inactivation of
TSGs may take place at the transcriptional and pro-
tein levels (enhanced protein degradation, or
decreased expression because of promoter hyperme-
thylation), it usually results from partial loss of the
gene, or even loss of the entire gene. According to
Knudson,34 the inactivation of a TSG takes place in
two steps. The first is usually a point mutation, or a
small deletion, whereas the second typically consists
of a large deletion of part of a chromosome that
involves the gene. Although it has recently been
demonstrated that monoallelic inactivation may be
sufficient,35 demonstration of deletions is still quite
informative regarding assessment of the role of a spe-
cific TSG in a particular type of tumour. Searching
for specific areas of the genome where gene deletions
(LOH) commonly occur in a determinate type of
Table 5. Correlation between FISH and immunohistochem-
istry (IHC) in 28 cases; three cases with heterogeneous


















Table 6. Correlation between SNP array and immunohistochemistry (IHC) in 28 cases; three cases with heterogeneous
alteration of PTEN are excluded
IHC Hscore
SNP array
Two copies Three copies One copy Focal deletion Deletion plus duplication of the second allele
0–40 6 4 2 3
41–100 2 4 2
101–200 2
201–300 1 1 1
Table 7. Correlation between FISH, SNP array and multiplex ligation-dependent probe amplification (MLPA) in three cases
with heterogeneous PTEN FISH patterns
SNP array FISH MLPA IHC staining
Case 10 Polysomy (three copies) Polysomy (44%)
Normal (56%)
Normal Heterogeneous
Case 15 One allele deleted plus duplication of the second allele Deleted (42%)
Normal (58%)
Normal Negative
Case 22 One allele deleted plus duplication of the second allele Polysomy (40%)
Normal (60%)
Normal Heterogeneous
© 2014 John Wiley & Sons Ltd, Histopathology, 65, 371–388.
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tumour is important, because it may lead to the rec-
ognition of TSGs that are involved in the development
or progression of such a tumour. PTEN is among the
most frequently lost or mutated TSGs, with a fre-
quency of monoallelic mutations estimated at 50–
80% in EC, glioblastoma, and prostate cancer, and at
30–50% in breast, colon and lung tumours.14 Com-
plete loss of PTEN is observed at the highest frequen-
cies in EC and glioblastoma.7 Detection of gene
deletions not only helps in understanding the molecu-
lar mechanisms underlying the development of can-
cer, but also provides important information for
disease diagnosis and prognosis.20,25 Identification of
deletions (LOH) may be carried out by different tech-
niques, including karyotyping,36 microsatellite poly-
merase chain reaction (PCR),37 comparative genomic
hybridization,38 FISH,39 MLPA,40 and SNPA.41
Fluorescence in-situ hybridization is a good method
for identifying deletions in tumour cells.25 It usually
requires the identification of the deleted target gene
with a locus-specific probe, in combination with pres-
ervation of the corresponding chromosomal centro-
mere, with the appropriate centromeric probe. It has
limited value in detecting small deletions.42 FISH
analysis has some advantages over molecular analy-
sis, particularly regarding correlation with morphol-
ogy and assessment of tumour heterogeneity.43
However, one of the major limitations of detecting
deletions in tissue sections by FISH is that part of the
cell can be lost during the sectioning process, leading
to artificially induced deletions in a significant per-
centage of nuclei.42 To decrease the false-positive
rate, the literature recommends using centromeric
probes as controls, as well as evaluation of a substan-
tial number of cells.32 The usefulness of FISH in the
evaluation of PTEN has been evaluated in carcino-
mas of the prostate,25 rectum,44 and stomach.45. In
prostate cancer, PTEN alterations, as analysed by
FISH, have been shown to have prognostic impor-
tance.25
In the MLPA technique, genomic DNA is hybridized
in solution to probe sets, each of which consists of
two halves. One half consists of a target-specific
sequence (20–30 bp),40 and the other half also has a
target-specific sequence at one end (25–43 bp) and a
universal primer sequence at the other, but has a
variable-length random fragment in between (19 and
370 bp) to generate the size differences in the probes
that are necessary to allow electrophoretic resolution.
The amounts of ligated probe produced will be pro-
portional to the target copy number, and, after PCR
amplification, the relative peak heights indicate dele-
tion or duplication of the target sequence. MLPA has
proven to be a highly sensitive and accurate tool for
detecting copy number changes.
Single nucleotide polymorphism array enables
simultaneous detection of a large number of DNA
polymorphic loci in a simple way. Single nucleotide
polymorphism array provides a high-throughput,
high-resolution approach to genotypic analysis that
includes assessment of LOH of chromosomal regions
based on paired normal and tumour samples from
the same patients.41 The application of informatics
tools to this technique may allow the identification of
LOH in many loci, and also the hierarchical cluster-
ing of cancers on the basis of shared LOH patterns.
Resolution varies according to the type of array, but
LOH may be resolved at least to approximately 3 Mb,
or 100 SNPs, in 100K arrays. Further technical
developments make SNPA capable of analysing both
signal intensity variations and changes in allelic com-
position in parallel. Single nucleotide polymorphism
array can also detect both copy number changes and
copy-neutral LOH events. The Human CytoSNP array
(Illumina) was used in this study, and is able to
detect 240 000 SNPs evenly distributed across the
genome.
ECs can be divided into two subtypes with different
clinicopathological and molecular characteristics.46
Endometrioid carcinomas (EECs) (85%) are usually
low-grade, oestrogen-dependent tumours.47 Serous
carcinomas (SCs), which represent the prototype of
non-endometrioid carcinomas (15%), are more
aggressive, are independent of oestrogen, and develop
in postmenopausal women. The molecular alterations
of EEC and SC are different; abnormalities in PTEN
occur in 40% of EECs. LOH at 10q23 frequently coex-
ists with somatic PTEN mutations, which are also
found in 37–61% of EECs.48 Assessment of PTEN by
immunohistochemistry or FISH may help in classify-
ing difficult cases.
In the present study, we developed a standardized
protocol for evaluation of PTEN by FISH, and we also
assessed PTEN status by FISH in a series of 31 ECs.
The same cases were subjected to SNPA, MLPA, and
immunohistochemistry. The results show good con-
cordance between FISH and SNPA or MLPA for ECs
with a normal PTEN copy number (all 11 cases with
two copies of PTEN by SNPA had a normal copy
number by FISH, and a concordant diploid pattern
between FISH and MLPA was seen in 15 of 17 cases).
Moreover, there was good correlation between FISH
and SNPA in assessment of the presence of large dele-
tions (two cases), if we exclude the tumours in which
a deletion of PTEN coexisted with duplication of the
second allele (five cases). In these cases, SNPA was
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superior to FISH and MLPA, because FISH could not
identify one of the two alleles as a duplicated one.
Finally, FISH was superior to SNPA and MLPA in
detecting the presence of gene copy number varia-
tion, in the context of morphology. This was particu-
larly obvious for the three tumours with a
heterogeneous distribution of tumour cells with differ-
ent pattern of PTEN copy number variation. In a pre-
vious study,33 a heterogeneous distribution of PTEN
staining was seen in 27% of cases, and correlated
with different expression levels of putative targets of
AKT (BAD, p27, and NFjB; data not shown).
Interestingly, nine ECs had three copies of PTEN
(polysomy), and in this group there was complete
agreement between FISH and SNPA. Polysomy was
more frequent among SCs (three of four cases, one of
them heterogeneous) than among EECs (nine of 27
cases, one of them heterogeneous), probably reflecting
the frequent presence of chromosomal instability in
SCs. Six of these nine tumours were interpreted as
showing PTEN amplification by MLPA. The results
suggest that FISH and SNPA are superior to MLPA in
assessing PTEN triploidy. Interestingly, the PTEN lev-
els in the nine tumours with an extra copy of PTEN,
as measured by immunohistochemistry, were similar
to the levels in tumours with a normal PTEN copy
number (P = 0.68). This suggests that the presence
of an additional copy of PTEN does not have an
impact on protein production. However, it is worth
mentioning that the area that contained three copies
of PTEN had a greater correspondence with the area
showing increased PTEN immunostaining than the
area with two copies in two of the three heteroge-
neous tumours. The biological role of polysomy in
altering the function of oncogenes or TSGs is under
debate. Polyploidy at chromosome 17, where HER2 is
located, occurs in one-third of breast carcinomas. It
has been shown that polysomy 17 is mechanistically
distinct from HER2 amplification. Polysomy at chro-
mosome 17, without HER2 amplification, does not
seem to significantly increase HER2 mRNA or HER2
protein levels in many cases, although there is a low
to moderate increase in HER2 level in some cases.
Breast cancers with extra copies of chromosome 17
resemble HER2-negative tumours according to stan-
dard pathological criteria, including tumour grade,
and hormonal status. Even more perplexing is the
presence of extra copies of TSGs, such as PTEN,
which are typically inactivated by loss of function
molecular events. In ECs, polysomy at chromosome
10 has been described previously. It may occur sepa-
rately, or may coexist with polysomy in other chro-
mosomes, such as chromosome 1 and chromosome
8. Several studies have shown that polysomy at chro-
mosome 10 is more frequent in EC than in endome-
trial hyperplasia, and that it is more frequent in
tumours with higher histological grade.48 Whether
polysomy at chromosome 10 is related to disturbance
of PTEN expression, or simply reflects the presence of
chromosomal instability, is still unknown. However,
the results of our study show that, as for HER2 in
breast carcinoma, polysomy at the PTEN loci does
not result in increased PTEN protein levels.19,36 Inter-
estingly, polysomy at chromosomal areas involving
well-known TSGs or genes involved in DNA repair
(RB1, p53, APC, BRCA1, BRCA2, and NF1) has been
reported.49
It is worth mentioning that five tumours showed
deletion of one copy of PTEN and duplication of the
second allele. Although not statistically significant,
perhaps because of the small number of cases, these
tumours showed a trend for decreased protein expres-
sion levels (eight of nine had Hscores of <100), sug-
gesting that the biological significance of the deleted
copy is more important than that of duplication of
the second allele. Interestingly, one of the heteroge-
neous tumours showed a PTEN deletion in one area
and a normal PTEN number in another area by FISH
(a PTEN deletion with duplication of the second allele
by SNPA), and PTEN immunostaining was negative
in both. We may speculate about the molecular basis
of this interesting subgroup of tumours. Polysomy is
usually a consequence of mis-segregation during
mitosis, which happens in tumours with chromo-
somal instability, and there are many findings show-
ing that ECs with PTEN alterations have genomic
instability. We may hypothesize that, in the presence
of PTEN alteration, chromosomal instability can lead
to the development of polysomy at some chromo-
somal loci, chromosome 10 among them. In this
regard, it is worth noting that deletion of PTEN was
seen in eight of 31 cases (26%), and in five of these
eight cases there was duplication of the second allele.
In other words, the polysomy at chromosome 10 was
seen in more than half of the tumours showing dele-
tion of PTEN.
In summary, a combination of these techniques is
helpful for assessment of PTEN copy number changes
in ECs. The combination of FISH and SNPA seems to
be particularly helpful. Fluorescence in-situ hybridiza-
tion allows much better assessment of tumour hetero-
geneity, whereas SNPA is helpful in identifying
tumours with deletion of PTEN and duplication of the
second allele, which appear as normal diploid by
FISH. The combination of all of these techniques,
together with immunohistochemistry, is helpful in
© 2014 John Wiley & Sons Ltd, Histopathology, 65, 371–388.
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interpreting the biological significance of polysomy at
the PTEN locus in chromosome 10. Discrepancies
between the results obtained with these techniques
and those obtained with immunohistochemistry may
be explained by the presence of PTEN mutations and
alterations in PTEN translation. Our results suggest
that a combination of FISH and immunohistochemis-
try may be of some help in assessing PTEN status in
routine practice.
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